7/105 sources · 3 publishersUpdated Nov 10, 17:36 UTC
Hims & Hers posts 49% revenue jump but subscriber loss, cuts guidance and price target
Hims & Hers Health reported third‑quarter 2026 revenue up 49% year‑over‑year to $890.4 million, while its subscriber base fell by about 100,000 to 2.8 million. Gross margins slipped to 57% as lower‑margin branded weight‑loss products scaled. The company lowered its full‑year adjusted EBITDA guidance to $257‑$277 million and analysts trimmed the stock’s price target to $32.
Why it matters
Needham and Truist reduced their price targets to $32, indicating a lower upside for investors. The revised EBITDA range narrows expected cash flow, which may affect valuation models.
Key facts
- 1Q3 2026 revenue was $890.4 million, a 49% increase year‑over‑year. investing.com
- 2Subscriber count declined to 2.8 million, down roughly 100,000 sequentially. finance.yahoo.com
- 3Gross margins fell to 57%, about seven points quarter‑over‑quarter. finance.yahoo.com
- 4Full‑year 2026 adjusted EBITDA guidance was reduced to $257‑$277 million. finance.yahoo.com
- 5Needham cut its price target for HIMS to $32 from $42. tradingview.com
- 6Truist reiterated a Hold rating with a $32 price target. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.